---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-26-000031"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T05:00:09.570769+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific Q1 2026 net sales $5.20B (+11.6% reported), adj EPS $0.80 (guidance $0.78-$0.80)

## Summary
- GAAP EPS $0.90 vs $0.45 YoY; adjusted EPS $0.80 vs $0.75 YoY, at top of guidance.
- Cardiovascular segment net sales $3.50B (+13.5% reported); MedSurg $1.70B (+7.8% reported).
- FY2026 guidance: organic growth 6.5-8.0%; adj EPS $3.34-$3.41. Q2: organic growth 5.0-7.0%; adj EPS $0.82-$0.84.
- WATCHMAN FLX trial (CHAMPION-AF) met all endpoints; FARAPULSE PFA showed superior long-term AF outcomes.
- Acquired Valencia Technologies (eCoin system for urge incontinence); elected Cathy Smith and Christophe Weber to board.

## SEC filing metadata
- accession: 0000885725-26-000031
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572526000031/0000885725-26-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572526000031/bsx-20260422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-26-000031
- JSON: https://secwatch.observer/filing/0000885725-26-000031.json
- Plain text: https://secwatch.observer/filing/0000885725-26-000031.txt

## Key facts
- Earnings Releases
  BOSTON SCIENTIFIC CORP reported first quarter ended March 31, 2026 results: revenue $5.203 billion, net income $1.341 billion or $0.90 per share (EPS), EPS $0.80.
  - Period: first quarter ended March 31, 2026
  - Revenue: $5.203 billion
  - Net income: $1.341 billion or $0.90 per share (EPS)
  - EPS: $0.80
  - Result: reported results
  source text: (EX-99.1) --- Boston Scientific announces results for first quarter 2026 Marlborough, Mass. (April 22, 2026) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported basis and 9.4 percent on an operational 1 and organic 2 basis, all compared to the prior year period. The
  evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572526000031/0000885725-26-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.